Alkermes initiates FORWARD-4 and FORWARD-3 efficacy research in pivotal clinical program for ALKS 5461 Alkermes plc today announced the initiation of Forwards-3 and Forwards-4, two of the three planned phase 3 core efficacy research in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medication with a novel mechanism of action for the adjunctive treatment of main depressive disorder . These studies will measure the efficacy and safety of ALKS 5461 in patients experiencing MDD who have got an inadequate response to generally prescribed drugs, including selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors . Approximately two-thirds of sufferers who are diagnosed with MDD usually do not adequately respond to initial antidepressant therapy.D., Chief Medical Officer of Alkermes.St. Louis Post-Dispatch: Missouri Lags Behind In Insurance Prices Transparency Connecticut, Kansas and Illinois are among a long list of says and the District of Columbia which have some kind of authority to review insurance charges, meaning pricing, before plans are sold. But that kind of authority does not can be found in Missouri. The Show-Me State is among the only states that will not be capable of review medical health insurance rates. Wyoming behind is close; it has only the capability to review rates for health maintenance businesses, or HMOs. Advocates say it's time for a switch in Missouri . Related StoriesGreater evidence-based help needed for depressed employees – New report from The Work FoundationProviding critical security for individuals in the health care industryDiagnosing traumatic brain damage through a blood test: an interview with Dr KorleyWBUR: Mass.